Press Releases

Investor Resources
Contact Us
Investor ResourcesPress Releases

Press Releases

Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 p.m. EDT


June 27, 2023

Cardiol Therapeutics Announces Year-End 2022 Update on Operations


March 29, 2023

Cardiol Therapeutics Announces Study Results from Collaborating Research Center Demonstrating Cardioprotective Effects of Cannabidiol in a Model of Heart Failure


March 7, 2023

Cardiol Therapeutics Announces First Patient Enrolled in Phase II Study Evaluating CardiolRx™ for the Treatment of Recurrent Pericarditis


January 17, 2023

Cardiol Therapeutics Commences Multi-center Phase II Pilot Study of CardiolRx™ for the Treatment of Recurrent Pericarditis


December 12, 2022

Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement


November 14, 2022

Cardiol Therapeutics Announces Study Results Demonstrating Protective Effects of CardiolRx™ in a Model of Acute Pericarditis


November 7, 2022

Cardiol Therapeutics Prioritizes Phase II Clinical Programs in Underserved Heart Diseases


October 25, 2022

Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating CardiolRx™ Inhibits and also Promotes Reversal of Mechanisms Leading to Cardiac Fibrosis


October 3, 2022

2025 Cardiol Therapeutics. All right reserved.